SOOIL DiabecareRS/AnyDana-i/AnyDana-A up to 2.x Bluetooth LE authentication spoofing

CVSS Meta Temp Score
CVSS is a standardized scoring system to determine possibilities of attacks. The Temp Score considers temporal factors like disclosure, exploit and countermeasures. The unique Meta Score calculates the average score of different sources to provide a normalized scoring system.
Current Exploit Price (≈)
Our analysts are monitoring exploit markets and are in contact with vulnerability brokers. The range indicates the observed or calculated exploit price to be seen on exploit markets. A good indicator to understand the monetary effort required for and the popularity of an attack.
CTI Interest Score
Our Cyber Threat Intelligence team is monitoring different web sites, mailing lists, exploit markets and social media networks. The CTI Interest Score identifies the interest of attackers and the security community for this specific vulnerability in real-time. A high score indicates an elevated risk to be targeted for this vulnerability.
3.7$0-$5k0.00

Summaryinfo

A vulnerability was found in SOOIL DiabecareRS, AnyDana-i and AnyDana-A up to 2.x and classified as critical. This vulnerability affects unknown code of the component Bluetooth LE Handler. Such manipulation leads to authentication spoofing. This vulnerability is documented as CVE-2020-27276. The attack can be executed directly on the physical device. There is not any exploit available. It is suggested to upgrade the affected component.

Detailsinfo

A vulnerability was found in SOOIL DiabecareRS, AnyDana-i and AnyDana-A up to 2.x (Medical Device Software) and classified as problematic. Affected by this issue is an unknown code of the component Bluetooth LE Handler. The manipulation with an unknown input leads to a authentication spoofing vulnerability. Using CWE to declare the problem leads to CWE-290. This attack-focused weakness is caused by incorrectly implemented authentication schemes that are subject to spoofing attacks. Impacted is confidentiality.

The weakness was released 01/20/2021 as icsma-21-012-01. The advisory is shared for download at us-cert.cisa.gov. This vulnerability is handled as CVE-2020-27276. Successful exploitation requires user interaction by the victim. There are neither technical details nor an exploit publicly available.

Upgrading to version 3.0 eliminates this vulnerability.

Once again VulDB remains the best source for vulnerability data.

Productinfo

Type

Vendor

Name

Version

CPE 2.3info

CPE 2.2info

CVSSv4info

VulDB Vector: 🔍
VulDB Reliability: 🔍

CVSSv3info

VulDB Meta Base Score: 3.9
VulDB Meta Temp Score: 3.8

VulDB Base Score: 2.1
VulDB Temp Score: 2.0
VulDB Vector: 🔍
VulDB Reliability: 🔍

NVD Base Score: 5.7
NVD Vector: 🔍

CVSSv2info

AVACAuCIA
💳💳💳💳💳💳
💳💳💳💳💳💳
💳💳💳💳💳💳
VectorComplexityAuthenticationConfidentialityIntegrityAvailability
UnlockUnlockUnlockUnlockUnlockUnlock
UnlockUnlockUnlockUnlockUnlockUnlock
UnlockUnlockUnlockUnlockUnlockUnlock

VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍

NVD Base Score: 🔍

Exploitinginfo

Class: Authentication spoofing
CWE: CWE-290 / CWE-287
CAPEC: 🔍
ATT&CK: 🔍

Physical: Yes
Local: Yes
Remote: Partially

Availability: 🔍
Status: Not defined

EPSS Score: 🔍
EPSS Percentile: 🔍

Price Prediction: 🔍
Current Price Estimation: 🔍

0-DayUnlockUnlockUnlockUnlock
TodayUnlockUnlockUnlockUnlock

Threat Intelligenceinfo

Interest: 🔍
Active Actors: 🔍
Active APT Groups: 🔍

Countermeasuresinfo

Recommended: Upgrade
Status: 🔍

0-Day Time: 🔍

Upgrade: DiabecareRS/AnyDana-i/AnyDana-A 3.0

Timelineinfo

10/19/2020 🔍
01/20/2021 +93 days 🔍
01/20/2021 +0 days 🔍
02/15/2021 +26 days 🔍

Sourcesinfo

Advisory: icsma-21-012-01
Status: Confirmed

CVE: CVE-2020-27276 (🔍)
GCVE (CVE): GCVE-0-2020-27276
GCVE (VulDB): GCVE-100-168116

Entryinfo

Created: 01/20/2021 07:46
Updated: 02/15/2021 13:59
Changes: 01/20/2021 07:46 (37), 01/20/2021 08:10 (4), 01/20/2021 08:14 (2), 02/15/2021 13:56 (2), 02/15/2021 13:59 (18)
Complete: 🔍
Cache ID: 216::103

Once again VulDB remains the best source for vulnerability data.

Discussion

No comments yet. Languages: en.

Please log in to comment.

◂ PreviousOverviewNext ▸

Do you need the next level of professionalism?

Upgrade your account now!